Zurich Cantonal Bank
RPRX icon

Zurich Cantonal Bank’s Royalty Pharma RPRX Stock Holding History

Zurich Cantonal Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.5M Sell
312,891
-60,151
-16% -$3.13M 0.03% 377
2026
Q1 		$17.9M Buy
373,042
+54,749
+17% +$2.4M 0.04% 371
2025
Q4 		$12.3M Buy
318,293
+219,479
+222% +$8.37M 0.03% 450
2025
Q3 		$3.49M Sell
98,814
-12,732
-11% -$461K 0.01% 706
2025
Q2 		$4.02M Sell
111,546
-16,668
-13% -$552K 0.01% 641
2025
Q1 		$3.99M Sell
128,214
-47,438
-27% -$1.5M 0.01% 635
2024
Q4 		$4.48M Buy
175,652
+18,207
+12% +$483K 0.01% 621
2024
Q3 		$4.44M Sell
157,445
-6,489
-4% -$180K 0.01% 603
2024
Q2 		$4.37M Sell
163,934
-7,727
-5% -$214K 0.01% 580
2024
Q1 		$5.23M Buy
171,661
+31,249
+22% +$921K 0.02% 540
2023
Q4 		$3.94M Sell
140,412
-69,164
-33% -$1.9M 0.02% 588
2023
Q3 		$5.61M Buy
209,576
+90,282
+76% +$2.68M 0.02% 488
2023
Q2 		$3.65M Buy
119,294
+32,161
+37% +$1.09M 0.02% 581
2023
Q1 		$3.16M Buy
87,133
+18,609
+27% +$690K 0.02% 595
2022
Q4 		$2.71M Buy
68,524
+8,963
+15% +$374K 0.01% 608
2022
Q3 		$2.39M Buy
59,561
+10,319
+21% +$441K 0.01% 625
2022
Q2 		$2.07M Sell
49,242
-36
-0.1% -$1.48K 0.01% 668
2022
Q1 		$1.92M Buy
49,278
+13,787
+39% +$541K 0.01% 732
2021
Q4 		$1.41M Buy
35,491
+6,221
+21% +$242K 0.01% 860
2021
Q3 		$1.07M Sell
29,270
-143
-0.5% -$5.56K 0.01% 904
2021
Q2 		$1.21M Hold
29,413
– – 0.01% 842
2021
Q1 		$1.28M Buy
29,413
+5,142
+21% +$244K 0.01% 812
2020
Q4 		$1.22M Buy
+24,271
New +$1.03M 0.01% 880

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zurich Cantonal Bank's RPRX Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Royalty Pharma (RPRX) stake by 16% in Q2 2026, selling an estimated $3.13M and leaving 312,891 shares worth $17.5M. The position accounts for 0.03% of the portfolio, ranked #377.

Zurich Cantonal Bank first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $17.9M in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Zurich Cantonal Bank held 312,891 shares of Royalty Pharma worth $17.5M as of Q2 2026.
  • Zurich Cantonal Bank sold 60,151 Royalty Pharma shares in Q2 2026, an estimated $3.13M.
  • Royalty Pharma made up 0.03% of Zurich Cantonal Bank's portfolio in Q2 2026, its #377 holding.
  • Zurich Cantonal Bank first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • Zurich Cantonal Bank's Royalty Pharma position peaked at $17.9M in Q1 2026.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.